关于海湾合作委员会国家生物类似药物价值框架的专家共识建议
Khalid A Alnaqbi1,2,3, Ahmed Al-Jedai4,5, Mohamed Farghaly6
1Rheumatology Division, Sheikh Tahnoon Medical City and Tawam Hospital, Al Ain, UAE. kalnaqbi@gmail.com.
Therapeutic innovation & regulatory science
|October 31, 2024
概括
为海湾合作委员会 (GCC) 国家制定了一个新的生物类似价值框架,强调信任,成本节约和当地背景. 教育举措和激励措施是促进所有利益相关者采用生物类似药物的关键.
科学领域:
- 制药政策 制药政策
- 卫生经济学 卫生经济学
- 药物开发 药物开发
背景情况:
- 生物类似药的采用在全球范围内有所不同,受政策和利益相关方参与的影响.
- 制定量身定制的框架对于优化生物类似药在各种医疗保健市场的普及至关重要.
- 海湾合作委员会 (GCC) 地区为生物类似融合提供了独特的机会和挑战.
研究的目的:
- 开发一个生物类似价值框架,以满足海湾合作委员会 (GCC) 国家的需求.
- 通过专家的共识,确定影响生物类似药物的采用的主要因素.
- 为该地区的政策制定者和利益相关者提供可行的建议.
主要方法:
- 专家小组会议与来自五个海湾合作委员会国家 (阿联,沙特阿拉伯,科威特,阿曼,卡塔尔) 的十位主要论领袖于2022年11月举行.
- 讨论围绕一个概念生物类似物价值框架和对现有生物类似物政策的审查进行.
- 在海湾合作委员会 (GCC) 地区积极影响生物类似药的因素分析.
主要成果:
- 关于海湾合作委员会国家生物类似价值框架的协议,以信任,成本节约和上下文因素为中心.
- 强调教育举措,以建立利益相关者的信任和有关生物类似药的知识.
- 承认激励和实施努力是生物类似药物采用的关键驱动力.
结论:
- 拟议的生物类似价值框架是阿拉伯国家首个此类框架.
- 该框架旨在指导政策制定者在高收入和低收入到中等收入的海湾合作委员会国家促进生物类似药的采用.
- 成功实施需要解决信任,成本和上下文方面的考虑.
更多相关视频
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
4.9K
08:01Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
Published on: November 30, 2022
4.1K
相关概念视频
Bioequivalence: Overview
926
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
926
Drug Control Governance: Regulatory Bodies and Their Impact
144
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
144
Dose-Response Relationship: Potency and Efficacy
4.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.2K
Pharmacovigilance
778
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
778
